Bullish option flow detected in Crispr Therapeutics with 1,714 calls trading, 1.1x expected, and implied vol increasing over 1 point to 57.50%. Jan-25 80 calls and 8/30 weekly 43 puts are the most active options, with total volume in those strikes near 1,100 contracts. The Put/Call Ratio is 0.37. Earnings are expected on November 4th.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Mid-Cap Stocks: CRSP Offers Tremendous Growth Potential With Inherent Risks
- Crispr Therapeutics price target lowered to $60 from $66 at RBC Capital
- Crispr Therapeutics price target lowered to $59 from $60 at Stifel
- Crispr Therapeutics price target lowered to $59 from $67 at Barclays
- Crispr Therapeutics price target lowered to $94 from $112 at Chardan